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Background: Odontogenic diseases can be a risk factor for life-threatening infection in patients with hematologic
malignancies during chemotherapy that induces myelosuppression of variable severity. Previous studies noted the
necessity of the elimination of all odontogenic foci before hematopoietic stem cell transplantation. To enable
planning for the adequate dental intervention, the oral medicine team must understand the general status of
patient and the intensity of the chemotherapy, which is sometimes difficult to be fully appreciated by dental staff.
Therefore, a simplified grading would facilitate the sharing of information between hematologists, dentists and oral
hygienists. This study aimed to introduce our myelosuppression grading of chemotherapies for hematologic
malignancies and analyze the timing of occurrence of severe odontogenic infection.
Methods: 37 patients having received various chemotherapies for hematologic malignancies were enrolled. The
chemotherapy regimens were classified into four grades based on the persistency of myelosuppression induced by
chemotherapy. Mild myelosuppressive chemotherapies were classified as grade A, moderate ones as grade B, severe
ones as grade C, and chemotherapies that caused severe myelosuppression and persistent immunodeficiency (known
as conditioning regimens for transplant) as grade D. The timing of occurrence of severe odontogenic infection was
retrospectively investigated.
Results: Two patients (5.4%) had severe odontogenic infections after grade B or C chemotherapy. One occurred after
extraction of non-salvageable teeth; the other resulted from advanced periodontitis in a tooth that could not be
extracted because of thrombocytopenia. Both were de novo hematologic malignancy patients. During grade D
chemotherapy, no patients had severe odontogenic infections.
Conclusions: The simplified grading introduced in this study is considered a useful tool for understanding the
myelosuppressive state caused by chemotherapy and facilitating communication between medical and dental staff.
During the period around the primary chemotherapy, especially for de novo hematologic malignancy patients who
often received grade B to C myelosuppression chemotherapy, caution should be exercised for severe odontogenic
infection by the oral medicine team, irrespective of whether invasive treatment is to be performed.
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Chemotherapy and hematopoietic stem cell transplant-
ation (HSCT), as the treatment for hematologic malig-
nancy, result in myelosuppression and increase the
susceptibility of patients to severe infections. Dentists
and oral hygienists have important roles in managing
the oral health of these patients [1,2]. Although it is
recommended that all odontogenic foci that are poten-
tial sources of systemic infection be eliminated by the
appropriate prophylactic dental treatment prior to initi-
ation of chemotherapy [3-7], the extraction of suspected
infected teeth is controversial because abnormal bleed-
ing, insufficient wound healing and local infection can
delay medical treatment for the hematological disease
[8-10]. Therefore, invasive dental treatment should be
carefully planned and executed at the appropriate phase.
To enable planning for the invasive treatments (e.g. den-
tal extraction and subgingival scaling), the oral medicine
team must understand the general status of patient, the
intensity of the chemotherapy, and the schedule for future
treatment. Because it is sometimes difficult for dental staff
to appreciate fully the myelosuppressive intensity of vari-
ous chemotherapy regimens, a simplified grading would
facilitate the sharing of information between hematolo-
gists, dentists and oral hygienists. We attempted to estab-
lish at our hospital a system of grading chemotherapy by
its myelosuppressive intensity to allow the sharing of ap-
propriate information between medical and dental staff.
This retrospective study had two purposes, one of
which was to introduce our myelosuppression grading of
chemotherapies for hematologic malignancies. The other
was to investigate the timing of occurrence of severe
odontogenic infection, because few studies determined
the correlation between the myelosuppresive intensity of
chemotherapy and the occurrence of sever odontogenic
infection. We experienced two patients having odonto-
genic septicemia during chemotherapeutic treatment
and analyzed the timing of those occurrences.
Methods
A retrospective study was carried out in 37 patients hav-
ing received treatments for hematologic malignancies.
From January 2009 through December 2010, patients
were referred from the Division of Medical Oncology/
Hematology to the Department of Oral and Maxillofacial
Surgery at the Kobe University Hospital to be screened
for odontogenic foci.
When the first dental screening was performed, pa-
tient details, including age, gender and diagnosis were
obtained. At the same time, the dental staff was informed
by the hematologists of the intensity of the scheduled
chemotherapy, based on the myelosuppression grading.
The myelosuppressive intensity of grade A chemother-
apies included the following oral agents and infusions:tyrosine kinase inhibitors for chronic myeloid leukemia;
all-trans retinoic acid (ATRA) for acute promyelocytic
leukemia; fludarabine phosphate internal use or intraven-
ous drip, rituximab monotherapy, and etoposide internal
use for chronic lymphoid leukemia or malignant lymph-
oma; melphalan plus prednisone (MP) for multiple mye-
loma, etc. These chemotherapies were mostly performed
for outpatients and the myelosuppressive intensity was
mild. The myelosuppressive intensity of grade B chemo-
therapies that included many different regimens (e.g. con-
solidation regimens for leukemia; CHOP, ABVD and
ESHAP for malignant lymphoma) was moderate. The my-
elosuppressive intensity of grade C chemotherapies that
included remission induction therapy for acute leukemia
was severe. The chemotherapies that caused the most se-
vere myelosuppression and persistent immunodeficiency
(known as myeloablative conditioning regimens) were
classified as grade D. The chemotherapy regimens en-
countered in this study are shown in Table 1.
The dental status of all patients was evaluated by two
dentists (a resident of the postgraduate program and a
senior dentist in Oral Surgery). Screening consisted of
clinical examination of the hard and soft oral tissues and
radiographic survey, including panoramic and occasional
periapical films for symptomatic teeth. All dental com-
plications during treatment for hematologic malignan-
cies were recorded for each patient, including infections,
gingivitis, caries, pulpitis, apical periodontitis, marginal
periodontitis, and pericoronitis of the third molar. Dental
foci that caused infections during the period of immuno-
compromise were defined as apical and marginal peri-
odontitis, and symptomatic third molar. Additionally, a
complete blood count (hemoglobin, hematocrit, white
blood cells, platelets, etc.) was performed to avoid the risk
of infections and hemorrhage and to determine coagula-
tion status. After confirming that the patient could tolerate
invasive procedures, all symptomatic third molars and
non-salvageable teeth with advanced marginal or apical
periodontal disease were extracted with prophylactic anti-
biotic coverage to protect against oral and generalized
infections.
Any patients with local signs and symptoms consistent
with odontogenic infections (e.g. gingival swelling and/
or dental pain) were given a dental examination and
treated as necessary. The occurrence of minor (e.g. gin-
givitis, minor gingival bleeding, and toothache) or severe
(e.g. cellulitis and sepsis) odontogenic infections was
recorded and monitored throughout the chemotherapy.
Detailed clinical courses of severe odontogenic infections
were retrospectively analyzed.
This study was approved by the Medical Ethics Com-
mittee of Kobe University. This retrospective analysis
was completed within the guidelines of the Helsinki
declaration.
Table 1 Myelosuppression grading of chemotherapies for
hematologic malignancies
Myelosuppression grading
Grade A mild myelosuppression
Grade B moderate myelosuppression (2–3 weeks for bone
marrow recovery)
Grade C severe myelosuppression (4 weeks for bone marrow recovery)
Grade D severe myelosuppression and persistent immunodeficiency
Regimens
Grade B Consolidation therapy for leukemia:
DA (DNR, Ara-C); MA (MIT, Ara-C); high-dose Ara-C
Chemotherapy for Malignant lymphoma:
ABVD (ADR, BLM, VLB, DTIC); CHOP (CPA, ADR, VCR, PSL);
ESHAP (ETP, Ara-C, CDDP, mPSL); Hyper-CVAD/MA
(course 1: CPA, VCR, ADR, DEX, course 2: MTX, Ara-C, mPSL)
Grade C Remission induction therapy for acute leukemia:
ATRA, IDR, Ara-C; DCM (DNR, Ara-C, 6-MP); DNR, VCR, CPA,
L-Asp, PSL; HAM (high dose Ara-C, MIT); IDR, Ara-C
High-dose chemotherapy with peripheral blood stem cell harvest:
high dose VP-16
Salvage chemotherapy for T-cell lymphoma:
SMILE (MTX, ETP, IFM, L-Asp, DEX)
Grade D Conditioning regimen for transplant:
MCVC (MCNU, CBDCA, ETP, CPA); HD-ICE (IFM, CBCDA, VP-16);
Flu/BU; Flu/Mel/TBI; TBI/CY
ADR adriamycin, Ara-C cytarabine, BLM bleomycin, BU Busulfan, CBDCA
carboplatin, CDDP cisplatin, CPA/CY cyclophosphamide, DEX dexamethasone,
DNR daunorubicin, DTIC dacarbazine, ETP/VP-16 etoposide, Flu fludarabine, IDR
idarubicin, IFM ifosfamide, L-Asp L-asparaginase, MCNU ranimustine, Mel
melphalan, MIT mitoxantrone, mPSL methylprednisolone, MTX methotrexate,
PSL prednisolone, TBI total body irradiation, VCR vincristine, VLB vinblastine,
6-MP 6-mercaptopurine.
Table 2 Patient characteristics
Number of patients
(n = 37) (%)





Acute myeloid leukemia 9 (24.3)
Acute lymphocytic leukemia 3 (8.1)
Acute biphenotypic leukemia 1 (2.7)
Malignant lymphoma 20 (54.1)
ATLL 3 (8.1)
Myelodysplastic syndrome 1 (2.7)
Medical treatment
Allogeneic BMT 7 (18.9)
Autologous PBSCT 4 (10.8)
Allogeneic PBSCT 1 (2.7)
CBT 2 (5.4)
Chemotherapy alone 23 (62.2)
Myelosuppression grading [courses]*
Grade B 34 (91.9) [64]
Grade C 18 (48.6) [22]
Grade D 15 (40.5) [15]
ATLL Adult T-cell leukemia/lymphoma, BMT Bone marrow transplantation,
PBSCT Peripheral blood stem cell transplantation.
CBT Cord blood transplantation.
*Course of treatment was counted. Some patients were graded several times.
Table 3 Degree of myelosuppression at the point of
dental extraction
Number of removed teeth 48
Number of patients* 10
WBC (/μl), median (range) 4100
Plt (×104/μl), median (range) 22.8
*Extraction was performed multiple times in five patients.
WBC white blood cell count.
Plt platelet count.
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Patient characteristics are summarized in Table 2. Medical
treatment for hematologic malignancy was transplant in
14 cases and chemotherapy alone in 23. The source of
stem cell was bone marrow in seven cases, peripheral
blood in five, and cord blood in two. Autologous trans-
plant was performed in four cases, whereas the remaining
ten patients received allogeneic transplant. Grade B che-
motherapies (moderate myelosuppression) were performed
in 34 patients (91.9%), grade C (severe myelosuppression)
in 18 (48.6%), and grade D (severe myelosuppression and
persistent immunodeficiency) in 15 (40.5%). Some patients
were graded several times. Total courses of grade B
chemotherapy were 64, grade C 22, and grade D 15.
The extraction of 45 non-salvageable teeth from 10 pa-
tients was performed following administration of prophy-
lactic antibiotics. On the day of operation, the median
white blood cell (WBC) count was 4100/μl (range: 1300–
11300) and the platelet count was 22.8 × 104/μl (range:
2.4-43.1) (Table 3). Platelet transfusion was required in
one patient.Although all patients received the scheduled chemo-
therapy with no alteration, interruption or delay caused
by the dental treatment, in two of the 37 patients (5.4%),
severe odontogenic infections occurred. These cases are
discussed in detail below.
Case 1
A 57-year-old female with B-cell lymphoma received
CHOP therapy (myelosuppression grade B) on the day of
hospitalization. The primary dental examination was
performed 10 days after the start of chemotherapy. When
bone marrow recovered on the 19th day, non-salvageable
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ation for subsequent autologous peripheral blood stem cell
transplantation.
During the night after the procedure, body tempera-
ture became elevated (Figure 1). Based on clinical find-
ings and laboratory data, the patient was diagnosed as
having sepsis with disseminated intravascular coagulation
resulting from infection after dental extraction. She re-
ceived intravenous antibiotics (meropenem, clindamycin
and teicoplanin). The patient duly recovered, and the
remaining non-salvageable teeth were extracted 10 days
after the onset of septicemia.
Case 2
A 67-year-old male with myelodysplastic syndrome-
derived overt leukemia received remission induction
therapy (IDA, Ara-C) on the day of hospitalization. He
underwent primary dental examination 5 days after the
start of grade C myelosuppression chemotherapy. Where-
as some asymptomatic teeth with advanced marginal peri-
odontitis were observed, invasive treatments (i.e. tooth
extraction) could not be provided because of thrombocy-
topenia caused by hematologic tumor and chemotherapy
(platelet count was 2.1 × 104/μl). Dental treatment was re-
stricted to conservative therapy such as oral hygiene
instruction.
When the WBC count dropped to 400/μl during the
20 days after initiation of chemotherapy, body tempera-
ture rose to 39°C (Figure 2). Pulse rate was over 100
beats per minute and respiratory rate was over 20Figure 1 Summary of case 1. G-CSF, granulocyte colony stimulating factobreaths per minute. The clinical examination revealed
severe gum pain and broad swelling around a tooth with
advanced marginal periodontitis. Although the results of
bacterial detection (2 trials of blood culture) were nega-
tive, clinical findings indicated the sepsis syndrome
resulting from odontogenic infection [11]. The infection
was resolved by administration of antibiotic drugs
(cefepime, hydrochloride and clindamycin).
Discussion
In our hospital, hematologists attempted to grade the
myelosuppressive properties of each chemotherapy regi-
men to facilitate effective communication with the oral
medicine team. Although dentists and oral hygienists
must understand the general status of patient and the
intensity of the chemotherapy to enable planning for the
adequate dental intervantion, it is sometimes difficult for
dental staff to appreciate fully the myelosuppressive in-
tensity of the chemotherapy regimens. The simplified
grading introduced in this study is considered a useful
tool for understanding the myelosuppressive state
caused by chemotherapy and facilitating communication
between medical and dental staff. Based on this grading,
we found that two patients out of 37 suffered from sep-
sis resulting from odontogenic diseases and investigated
the timing of those occurrences.
In case 1, the sepsis happened after the grade B
chemotherapy. The patient received granulocyte colony-
stimulating factor (G-CSF) because granulocytopenia oc-
curred (the nadir of the WBC count was 600/μl).r; BT, body temperature; EXT, tooth extraction; WBC, white blood cells.
Figure 2 Summary of case 2. G-CSF, granulocyte colony stimulating factor; BT, body temperature; EXT, tooth extraction; WBC, white blood cells.
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enced sepsis following invasive dental treatment 19 days
after the start of the first course of CHOP. Owing to the
chemotherapy and residual tumor, this patient may not
have recovered full immune function, despite having
apparently normal WBC count. In case 2, the patient suf-
fered sepsis after grade C chemotherapy. This chemother-
apy was initiated very rapidly after admission because
tumor growth was quite rapid. Although professional den-
tal care had not be performed before hospitalization and
his dental hygiene was so poor on primary dental examin-
ation, the delay in initiating chemotherapy that would
have been caused by pursuing dental treatment would
have been unacceptable. We noted that both patients were
de novo hematologic malignancy patients that were sick,
febrile and hemorrhagic owing to massive tumor volume,
and were thus in a myelodeficient state. Despite their ill-
ness, primary dental examination was important, given
that previous reports have suggested that prophylactic
dental treatment is a critical factor in reducing the occur-
rence of infections during chemotherapy [12]. The time
available for providing prophylactic dental treatment
influences the incidence of infection, but elimination
of all odontogenic foci takes considerable time [13-15].
Yamagata et al. recommended that the dental extraction
should be performed during remission and 10–14 days
before the start of conditioning [16]. Raber-Durlacher
et al. mentioned that the intervals between chemotherapy
cycles may provide a good opportunity for improving oraland periodontal health [17]. During neutropenia, invasive
procedures, such as periodontal probing, should be
avoided.
The findings of this study may indicate that myelo-
suppression grade B-to-C chemotherapies may place the
patient at the risky phase of experiencing severe odonto-
genic infections, perhaps because these types of chemo-
therapies are commonly given to patients with de novo
hematologic malignancies. These patients have immuno-
deficiency and thrombocytopenia resulting from un-
treated tumor volume and chemotherapy and, as seen in
the patients in this study, tend to have poor oral hygiene.
Immune status in these patients is hard to judge from
purely laboratory data. Thus, caution should be
exercised by the oral medicine team when considering
grade B to C chemotherapies especially for de novo
hematologic malignancy patients, irrespective of whether
invasive treatment is to be performed. In our study,
odontogenic septicemia did not occur in 15 patients dur-
ing grade D chemotherapy that had caused severe im-
munosuppression and persistent immunodeficiency. It is
clear that reduction of tumor volume by grade B-to-C
chemotherapy (known as induction or consolidation
chemotherapy) can be safely followed by HSCT therapy,
provided that adequate prophylactic dental treatments
during the intervals between chemotherapy cycles. This
hypothesis may be supported by one previous important
case report by Soga et al. [18]. In their report, the fre-
quency of febrile neutropenia decreased with increasing
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penia corresponded to the progress of periodontal treat-
ment. The dental interventions performed could have
decreased the occurrence of exacerbations of dental in-
fections in a subsequent phase, which may explain why
such exacerbations were not observed during HSCT.
The period around primary chemotherapy for de novo
hematologic malignancy patients is considered to be a
risky phase with regard to the development of severe
odontogenic infections owing to instability in the im-
mune system caused by the myelosuppressive chemo-
therapy and the untreated hematologic tumor. The oral
medicine team should be mindful of rectifying poor oral
hygiene to negate this risk with conservative therapies,
but dentists should avoid radical treatment during this
period. When the status of de novo hematologic malig-
nancy patients is improved by grade B or C chemotherapy,
invasive procedures should be performed rapidly during
the intervals between chemotherapy cycles, and com-
pleted before the initiation of grade D chemotherapy.
A standard dental management protocol for use in pa-
tients prior to chemotherapy would be useful adjunct to
treatment planning. Yamagata et al. have previously de-
scribed detailed criteria for minimal intervention treat-
ment of detrimental dental disorders before HSCT [19].
A prospective study is required to evaluate the effective-
ness of a newly designed dental treatment protocol com-
bined with myelosuppression grading of chemotherapy.
The main issues of this study were the small sample size,
the heterogeneity of study population with respect to
diagnosis as well as type of treatment, and the lack of
direct bacterial evidence from blood culture results. Oral
mucositis that is a common complication associated
with high-dose chemotherapy and can be a portal of
entry for systemic infection [20] as well as odontogenic
disease could not be evaluated in this study. The recent
study revealed that the dental/periodontal infections can
be easily overlooked or misdiagnosed, particularly when
symptoms on inflammation are masked by neutropenia
[21]. Therefore, the frequency of dental/periodontal in-
fections is likely underestimated. More studies are
needed on the relative contributions of odontogenic infec-
tions to local and systemic complications during the mye-
losuppressive chemotherapy. The use of myelosuppression
grading to aid in structuring prophylactic dental treatment
has great potential in reducing oral complications in pa-
tients with hematologic malignancies, but requires further
validations.
Conclusion
The simplified grading introduced in this study is con-
sidered a useful tool for understanding the myelosuppres-
sive state caused by chemotherapy and facilitating
communication between medical and dental staff. Duringthe period around the primary chemotherapy for de novo
hematologic malignancy patients, caution should be
exercised for the occurrence of severe odontogenic infec-
tion due to immunodeficiency resulting from untreated
tumor and poor oral hygiene.
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